--- title: "Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline" type: "News" locale: "en" url: "https://longbridge.com/en/news/287277446.md" description: "B Group, Inc. acquired 67,500 shares of Bright Minds Biosciences for approximately $5.43 million, representing about 4% of its U.S. equity assets. The investment reflects confidence in Bright Minds' drug pipeline, particularly its lead asset BMB-101 for drug-resistant epilepsy. Despite being a new position and not among B Group's top five holdings, Bright Minds has shown significant stock price growth, up nearly 175% over the past year. The company is well-funded with C$309.7 million in cash, supporting its development efforts." datetime: "2026-05-21T22:00:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287277446.md) - [en](https://longbridge.com/en/news/287277446.md) - [zh-HK](https://longbridge.com/zh-HK/news/287277446.md) --- # Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ## Key Points - B Group bought 67,500 shares of Bright Minds Biosciences in the first quarter. - The quarter-end value of the new stake was $4.93 million. - Transaction value equates to 4% of B Group, Inc.’s reportable U.S. equity assets - The new position, while notable, places Bright Minds Biosciences outside the fund’s top five holdings. - 10 stocks we like better than Bright Minds Biosciences › B Group, Inc. disclosed a new stake in **Bright Minds Biosciences** (NASDAQ:DRUG) in its May 15, 2026, SEC filing, acquiring 67,500 shares—an estimated $5.43 million trade based on quarterly average pricing. ## What happened According to a May 15, 2026, SEC filing, B Group, Inc. initiated a new position in Bright Minds Biosciences, purchasing 67,500 shares. The estimated transaction value is $5.43 million, calculated using the average closing price for the first quarter of 2026. The value of the stake at quarter-end was $4.93 million, a figure that includes both share purchases and movement in the company’s stock price during the period. ## What else to know - This is a new position for B Group, Inc., representing roughly 4% of reportable AUM as of March 31, 2026. - Top five holdings after the filing: - NASDAQ: ADMA: $28.90 million (21.4% of AUM) - NASDAQ: PALI: $19.97 million (14.8% of AUM) - NASDAQ: PRAX: $10.71 million (7.9% of AUM) - NASDAQ: CLLS: $10.40 million (7.7% of AUM) - NASDAQ: ZLAB: $8.48 million (6.3% of AUM) - As of Thursday, Bright Minds Biosciences shares were priced at $83.24, up nearly 175% over the past year and well outperforming the S&P 500, which is instead up about 25%. ## Company Overview Metric Value Price (as of market close May 14, 2026) $83.24 Market Capitalization $815 million Net Income (TTM) ($19.8 million) ## Company Snapshot - DRUG develops selective 5-HT receptor agonists targeting epilepsy, pain, and neuropsychiatric disorders, with a portfolio focused on 5-HT2C, 5-HT2A, and 5-HT2C/A compounds. - The firm operates a pre-clinical biotechnology model, generating value through research collaborations and intellectual property development rather than product sales. - It targets patients with severe neurological and psychiatric conditions, collaborating with research institutions and healthcare partners to advance clinical applications. Bright Minds Biosciences is a pre-clinical biotechnology company specializing in the development of next-generation serotonin-based therapeutics for neurological and neuropsychiatric conditions. The company leverages strategic collaborations with leading medical research institutions to accelerate innovation and expand its intellectual property portfolio. With a focus on high unmet medical needs, Bright Minds aims to establish a competitive edge through targeted drug development and scientific partnerships. ## What this transaction means for investors B Group is stepping into Bright Minds during a massive run higher, suggesting it sees additional upside tied to the company's drug pipeline (given the nature of pre-revenue biotechs). The company's most important asset remains BMB-101, a serotonin receptor agonist being developed for drug-resistant epilepsies. Management has been accelerating development efforts, with research and development spending climbing to C$18.7 million during the first six months of fiscal 2026, up from C$3.6 million a year earlier as clinical and preclinical programs advanced. Just as important, Bright Minds ended March with roughly C$309.7 million in cash and cash equivalents after completing a January equity offering that raised about $175 million. That gives the company substantial resources to fund development without the near-term financing pressure that often weighs on early-stage biotech firms. For long-term investors, this is still a high-risk, high-reward story. The company has no commercial revenue and remains loss-making. But with a well-funded balance sheet and pipeline progress, there are reasons to be bullish. ## Should you buy stock in Bright Minds Biosciences right now? Before you buy stock in Bright Minds Biosciences, consider this: The _Motley Fool Stock Advisor_ analyst team just identified what they believe are the **10 best stocks** for investors to buy now… and Bright Minds Biosciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when **Netflix** made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, **you’d have $475,063**!\* Or when **Nvidia** made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, **you’d have $1,369,991**!\* Now, it’s worth noting _Stock Advisor’s_ total average return is 994% — a market-crushing outperformance compared to 207% for the S&P 500. **Don't miss the latest top 10 list, available with _Stock Advisor_, and join an investing community built by individual investors for individual investors.** See the 10 stocks » _\*Stock Advisor returns as of May 21, 2026._ _Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Adma Biologics. The Motley Fool has a disclosure policy._ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [DRUG.US](https://longbridge.com/en/quote/DRUG.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [ADMA.US](https://longbridge.com/en/quote/ADMA.US.md) - [PALI.US](https://longbridge.com/en/quote/PALI.US.md) - [PRAX.US](https://longbridge.com/en/quote/PRAX.US.md) - [CLLS.US](https://longbridge.com/en/quote/CLLS.US.md) - [ZLAB.US](https://longbridge.com/en/quote/ZLAB.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) - [NFLX.US](https://longbridge.com/en/quote/NFLX.US.md) - [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md) - [09688.HK](https://longbridge.com/en/quote/09688.HK.md) - [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md) ## Related News & Research - [BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models](https://longbridge.com/en/news/286973840.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md) - [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md) - [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)